Variation in PPARG is Associated with Longitudinal Change in Insulin Resistance in Mexican Americans at Risk for Type 2 Diabetes

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2015 Jan 14

PMID 25584717

Citations 16

Authors

Mary Helen Black

Jun Wu

Miwa Takayanagi

Nan Wang

Kent D Taylor

Talin Haritunians

Enrique Trigo

Jean M Lawrence

Richard M Watanabe

Thomas A Buchanan

Anny H Xiang

Affiliations

Soon will be listed here.

Abstract

Context: Peroxisome proliferator-activated receptor gamma (PPARG) is a susceptibility locus for type 2 diabetes mellitus (T2DM). Although cross-sectional associations have been reported, primarily for Pro12Ala, few longitudinal studies in nondiabetic populations have been conducted.

Objective: This study aimed to examine whether and to what extent variation in PPARG is associated with longitudinal changes in anthropometric and metabolic traits in Mexican Americans at risk for T2DM.

Setting And Design: Subjects were participants of BetaGene, a family-based study of obesity, insulin resistance, and β-cell function, who completed a baseline and follow-up study visit (n = 378; mean followup, 4.6 ± 1.5 y). Phenotypes included body fat assessed by dual-energy x-ray absorptiometry; insulin sensitivity (SI), acute insulin response, and β-cell function (disposition index; DI) were estimated from iv glucose tolerance tests with Minimal Model analysis. Eighteen tag single nucleotide polymorphisms (SNPs) capturing variation in a 156-kb region surrounding PPARG were tested for association with changes in longitudinal traits. P-values were Bonferroni-corrected for multiple testing.

Results: Six SNPs (rs2972164, rs11128598, rs17793951, rs1151996, rs1175541, rs3856806) were significantly associated with rate of change in SI after adjustment for age, sex, and body fat percentage, but not with changes in adiposity. rs17793951 also had a significant effect on change in DI over time. Association between rs1175541 and change in SI varied by changes in adiposity such that only carriers of the minor allele who reduced body fat over followup improved SI. rs1306470 (captured Pro12Ala, r(2) = 0.9) was not associated with rates of change in any traits and its effects were not modified by changes in adiposity.

Conclusions: Variation in PPARG, but not Pro12Ala, contributes to declining SI and concomitant deterioration in β-cell function in Mexican Americans at risk for T2DM.

Citing Articles

Maternal genomic profile, gestational diabetes control, and Mediterranean diet to prevent low birth weight.

Ramos-Levi A, OConnor R, Barabash A, de Miguel M, Diaz-Perez A, Marcuello C iScience. 2024; 27(12):111376.

PMID: 39687027 PMC: 11648256. DOI: 10.1016/j.isci.2024.111376.

Association between PPAR polymorphisms and neurological functional disability of ischemic stroke.

Yan R, Qiu X, Dai Y, Jiang Y, Gu H, Jiang Y J Cereb Blood Flow Metab. 2024; 45(2):328-339.

PMID: 39161254 PMC: 11572223. DOI: 10.1177/0271678X241274681.

Preconceptional and in utero exposure of sheep to a real-life environmental chemical mixture disrupts key markers of energy metabolism in male offspring.

Ghasemzadeh-Hasankolaei M, Elcombe C, Powls S, Lea R, Sinclair K, Padmanabhan V J Neuroendocrinol. 2023; 36(1):e13358.

PMID: 38087451 PMC: 10841670. DOI: 10.1111/jne.13358.

PFAS and Potential Adverse Effects on Bone and Adipose Tissue Through Interactions With PPARγ.

Kirk A, Michelsen-Correa S, Rosen C, Martin C, Blumberg B Endocrinology. 2021; 162(12).

PMID: 34480479 PMC: 9034324. DOI: 10.1210/endocr/bqab194.

The association between expression of lncRNAs in patients with GDM.

Li Y, Li D, Cheng X Endocr Connect. 2021; 10(9):1080-1090.

PMID: 34289446 PMC: 8428044. DOI: 10.1530/EC-21-0227.

References

Martinez-Gomez L, Cruz M, Martinez-Nava G, Madrid-Marina V, Parra E, Garcia-Mena J . A replication study of the IRS1, CAPN10, TCF7L2, and PPARG gene polymorphisms associated with type 2 diabetes in two different populations of Mexico. Ann Hum Genet. 2011; 75(5):612-20. DOI: 10.1111/j.1469-1809.2011.00668.x. View

Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner A . The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord. 2000; 24(3):391-3. DOI: 10.1038/sj.ijo.0801191. View

Bhatt S, Misra A, Sharma M, Luthra K, Guleria R, Pandey R . Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol Ther. 2012; 14(9):828-34. PMC: 3429329. DOI: 10.1089/dia.2011.0277. View

Prakash J, Srivastava N, Awasthi S, Agarwal C, Natu S, Rajpal N . Association of PPAR-γ gene polymorphisms with obesity and obesity-associated phenotypes in North Indian population. Am J Hum Biol. 2012; 24(4):454-9. DOI: 10.1002/ajhb.22245. View

Delahanty L, Pan Q, Jablonski K, Watson K, McCaffery J, Shuldiner A . Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care. 2011; 35(2):363-6. PMC: 3263869. DOI: 10.2337/dc11-1328. View

Duran-Gonzalez J, Ortiz I, Gonzales E, Ruiz N, Ortiz M, Gonzalez A . Association study of candidate gene polymorphisms and obesity in a young Mexican-American population from South Texas. Arch Med Res. 2011; 42(6):523-31. PMC: 3230750. DOI: 10.1016/j.arcmed.2011.10.010. View

Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb S . Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord. 2000; 24(2):195-9. DOI: 10.1038/sj.ijo.0801112. View

Grundberg E, Small K, Hedman A, Nica A, Buil A, Keildson S . Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet. 2012; 44(10):1084-9. PMC: 3784328. DOI: 10.1038/ng.2394. View

Cole S, Mitchell B, Hsueh W, Pineda P, Beamer B, Shuldiner A . The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord. 2000; 24(4):522-4. DOI: 10.1038/sj.ijo.0801210. View

10.

Douglas J, Erdos M, Watanabe R, Braun A, Johnston C, Oeth P . The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes. 2001; 50(4):886-90. DOI: 10.2337/diabetes.50.4.886. View

11.

Evans D, WOLF A, Nellessen U, Ahle S, Kortner B, Kuhlmann H . Association between polymorphisms in candidate genes and morbid obesity. Int J Obes Relat Metab Disord. 2001; 25 Suppl 1:S19-21. DOI: 10.1038/sj.ijo.0801690. View

12.

Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa M . Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia. 2001; 44(7):925-6. DOI: 10.1007/s001250100558. View

13.

Nicklas B, van Rossum E, Berman D, Ryan A, Dennis K, Shuldiner A . Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes. 2001; 50(9):2172-6. DOI: 10.2337/diabetes.50.9.2172. View

14.

Gabriel S, Schaffner S, Nguyen H, Moore J, Roy J, Blumenstiel B . The structure of haplotype blocks in the human genome. Science. 2002; 296(5576):2225-9. DOI: 10.1126/science.1069424. View

15.

Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S . Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab. 2002; 87(8):3989-92. DOI: 10.1210/jcem.87.8.8732. View

16.

Doney A, Fischer B, Frew D, Cumming A, Flavell D, World M . Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet. 2002; 3:21. PMC: 137581. DOI: 10.1186/1471-2156-3-21. View

17.

Meirhaeghe A, Fajas L, Gouilleux F, Cottel D, Helbecque N, Auwerx J . A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol. 2003; 23(2):289-94. DOI: 10.1161/01.atv.0000051382.28752.fe. View

18.

Robitaille J, Despres J, Perusse L, Vohl M . The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec Family Study. Clin Genet. 2003; 63(2):109-16. DOI: 10.1034/j.1399-0004.2003.00026.x. View

19.

Boston R, Stefanovski D, Moate P, Sumner A, Watanabe R, Bergman R . MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther. 2004; 5(6):1003-15. DOI: 10.1089/152091503322641060. View

20.

Tai E, Corella D, Deurenberg-Yap M, Adiconis X, Chew S, Tan C . Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res. 2004; 45(4):674-85. DOI: 10.1194/jlr.M300363-JLR200. View